A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
Clinical trial NCT05067582 · COMPLETED
Trial details
- NCT number
- NCT05067582
- Sponsor
- Yamo Pharmaceuticals LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-25
- Primary completion
- 2024-06-18
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.